Eric I Tsao

Dr. Eric I Tsao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

Verified
Journal Article
Open access
PDF file
CCCindy Chao
Cindy Chao
SZShou-Feng Zhang
Shou-Feng Zhang
LCLi Chen
Li Chen
ETEric I Tsao
Eric I Tsao
Charles E. RupprechtCharles E. Rupprecht
Charles E. Rupprecht
Rabies immune globulin (RIG) is an indispensable component of rabies post-exposure prophylaxis (PEP) because it provides passive immunity to prevent this otherwise inescapably fatal disease in Category III exposed patients. Even with decades of development, RIG products are still criticized for their high cost, lot-to-lot variation, and potential safety issues. They remain largely unattainable in most developing regions of the world, where demand is highest. In recent years, monoclonal antibodies (MAbs) have become widely accepted as safer and more cost-effective alternatives to RIG products. As an example, SYN023 is a 1:1 cocktail of two humanized anti-rabies MAbs previously shown to display extensive neutralizing capabilities. Here, we further assessed the efficacy of SYN023 in animal models of rabies, and found that SYN023 afforded protection equal to a standard dose of human RIG (HRIG) at 0.03 mg/kg in Syrian hamsters and 0.1 mg/kg in beagles. Potential interference with vaccine-induced immunity was analyzed for the MAbs at these concentrations. While individual MAbs did not interfere with vaccine response, SYN023 at dosages of 0.1 mg/kg and above resulted in reduced neutralizing antibody titers similar to HRIG. Thus, the in vivo characterization of SYN023 supports its utility in human rabies PEP as an efficacious alternative to RIG products.

25 January 2021 in Clinical Pharmacology in Drug Development
Verified
Journal Article
Closed access
PDF file
JMJ. Bruce McClain
J. Bruce McClain
ACAriel Chuang
Ariel Chuang
SMSusan M. Moore
Susan M. Moore
ETEric I Tsao
Eric I Tsao

4 June 2024 in Vaccine
Verified
Journal Article
Closed access
BQBeatriz Puzon Quiambao
Beatriz Puzon Quiambao
RPRonald Allan Payumo
Ronald Allan Payumo
CRCamilo Roa
Camilo Roa
CBCharissa Fay Borja-Tabora
Charissa Fay Borja-Tabora
MMMay Emmeline Montellano
May Emmeline Montellano
JMJ. Bruce McClain
J. Bruce McClain

5 June 2025 in Vaccine
Verified
Journal Article
Open access
XLXiaoqiang Liu
Xiaoqiang Liu
JLJingyu Li
Jingyu Li
YZYongxian Zha
Yongxian Zha
ZWZhengxiong Wang
Zhengxiong Wang
YJYa Jiang
Ya Jiang
ETEric I Tsao
Eric I Tsao
The SYN023-006 study was conducted in WHO Category III rabies-exposed patient populations to assess the safety and efficacy of post-exposure prophylaxis that included either the monoclonal antibody mixture SYN023 or human rabies immunoglobulin (HRIG). This phase 3, double-blind, randomized, controlled trial was conducted at multiple clinical disease control sites in China. Patients were randomized 3:1 (stratified by study site) to wound infiltration with 0.3 mg/kg SYN023 or 20 IU/kg HRIG. All patients received thorough wound washing and 5 doses intramuscular Vero cell rabies vaccine. The composite primary study objective was to demonstrate: 1) superiority of Day 8 geometric mean (GM) concentration of serum rabies virus neutralizing antibodies (RVNA) with SYN023 versus HRIG (protocol-defined superiority margin: GM RVNA ratio 95 % confidence interval [CI] lower limit >1.2) and 2) no rabies in SYN023 recipients. Efficacy was evaluated in the Per-Protocol population. Safety endpoints included solicited and unsolicited adverse events (AEs) analyzed in all patients receiving any study treatment. ClinicalTrials.govNCT04644484. From 23 September 2020 to 26 June 2021, 537 male and 463 female patients were randomized (n = 750 SYN023, n = 250 HRIG). Day 8 GM RVNA was 4.339 IU/mL (standard error [SE]: 1.035) with SYN023 and 0.232 IU/mL (SE: 1.060) with HRIG. The SYN023:HRIG GM RVNA ratio was 18.695 (95 % CI: 16.440, 21.260) indicating superior RVNA with SYN023. No suspected rabies cases or deaths occurred. AEs were generally similar between treatment groups except greater local solicited AEs frequencies with HRIG (SYN023: 165/750 patients [22.0 %]; HRIG: 97/250 [38.8 %]). This study indicates that SYN023, a monoclonal antibody product, may be used as part of rabies post-exposure prophylaxis and provides superior protection sooner after exposure than HRIG.

30 November 2025 in Emerging Microbes & Infections
Verified
Journal Article
Open access
LCLei Cao
Lei Cao
JQJiagui Qu
Jiagui Qu
CZChuziyue Zhang
Chuziyue Zhang
RCRuihong Chen
Ruihong Chen
JWJinyue Wang
Jinyue Wang
ETEric I Tsao
Eric I Tsao